Best Cannabinoids in Skincare: A Formulator's Guide to CBD, CBG, and CBN in Skincare

Quick Answer: Cannabinoids, including CBD, CBG, CBN, CBC, and CBDv, represent a new generation of anti-inflammatory, antimicrobial, and barrier-supporting skincare actives backed by clinical research. Cannabinoids like CBG demonstrate even stronger anti-inflammatory activity than vitamin C in some studies. For formulators, these compounds offer non-psychoactive, plant-derived alternatives to synthetic actives, particularly for managing acne, environmental stress, and compromised skin barriers, with the added advantage of naturally broad-spectrum antimicrobial properties.

Key Takeaways

• Cannabinoids such as CBD, CBG, CBN, CBC, and CBDv provide anti-inflammatory, antimicrobial, and barrier-supporting benefits supported by clinical and preclinical research.

• Their formulation behavior depends on oxidative stability, solubility, receptor activity, and compatibility with emulsions, surfactants, and delivery systems.

• CBD remains the most validated option, offering sebostatic, anti-inflammatory, and collagen-protective effects with wide safety margins and strong sourcing standardization.

• CBG shows stronger anti-inflammatory and antioxidant activity than vitamin C in select assays and improves barrier strength at low topical concentrations.

• CBN supports overnight repair through calming, anti-inflammatory, and antimicrobial actions, while CBC and CBDv offer targeted anti-acne benefits via sebum and inflammation pathway modulation.

• Successful cannabinoid formulations require attention to stability, dosing between 0.1 and 3 percent, and COA-verified sourcing to maintain consistency and compliance.

• To scale cannabinoid skincare products with confidence, partner with Arvida Labs to source high-quality CBD, CBG, and CBN backed by documentation and formulation support.

Formulators working in cannabinoid skincare are increasingly refining how they use cannabinoids to drive performance, stability, and differentiation. CBD, CBG, and CBN, alongside other cannabinoids, present distinct chemical behaviors that influence how they integrate into emulsions, survive manufacturing stresses, and maintain consistency through shelf life. 

Their oxidative profiles, interaction with carrier systems, and compatibility with surfactants or actives matter just as much as their proposed functional benefits. As brands move toward cleaner inputs and tighter QC expectations, choosing the right cannabinoid is becoming a strategic decision rather than a simple ingredient swap. 

This guide highlights the characteristics that matter most to formulators so you can determine which cannabinoids support your intended texture, absorption profile, and formulation architecture, without compromising scalability or regulatory alignment.

Why Cannabinoids Are Gaining Ground in Professional Skincare

Cannabinoid-based skincare has gone from a marketing gimmick to an actual evidence-backed business idea. While CBD isolate has dominated the market since 2018, formulators are now exploring the unique pharmacological profiles of lesser-known cannabinoids, CBG, CBN, CBC, and CBDv, each coming with its own set of distinct advantages for targeting specific skin conditions.

The global CBD skincare market reached $2.486 billion in 2024 and is projected to grow to $7.834 billion by 2030 at 21.1% CAGR, but growth is increasingly concentrated in formulations that move beyond basic moisturizers into targeted anti-aging, anti-acne, and barrier-repair categories.

Cannabinoids interact with the skin's endocannabinoid system, a network of receptors (CB1, CB2, TRPV1, and others) found in keratinocytes, sebocytes, fibroblasts, and immune cells. This system regulates sebum production, inflammation, cell proliferation, and barrier function, which are key factors in conditions like acne, eczema, and premature aging. 

What separates cannabinoids from conventional botanical actives is their multi-pathway mechanism: they modulate inflammatory cytokines, demonstrate antimicrobial activity, and address multiple skin concerns simultaneously, all without requiring the high concentrations typical of traditional plant extracts. 

A November 2024 study published in the International Journal of Molecular Sciences confirmed that both CBD and CBG exhibited no cytotoxicity, mutagenicity, or skin sensitization, while demonstrating promise as protective agents against inflammation caused by air pollution.

Manufacturers working with white-label cannabinoid formulations are now requesting specific cannabinoid profiles rather than generic "hemp extract." The reason is straightforward: formulators need predictable, standardized activity. 

Cannabinoids deliver if sourced correctly and formulated with precision. Hemp-derived cannabinoids containing less than 0.3% delta-9-THC remain federally compliant in the U.S., though state laws vary. Formulators must make sure their cannabinoid sources are properly documented with third-party COAs verifying cannabinoid content, absence of heavy metals, pesticides, and microbial contamination. This is where sourcing bulk cannabinoids from trusted manufacturers becomes non-negotiable.

Best Cannabinoids for Skincare and Their Benefits

The cannabinoid category extends far beyond CBD, with each cannabinoid providing its own set of distinct pharmacological advantages. The following cannabinoids have the strongest clinical and preclinical support for topical skincare applications.

CBD (Cannabidiol)

CBD remains the most researched cannabinoid for skincare, with established efficacy across multiple dermatological conditions. As a non-psychoactive compound, CBD interacts primarily with TRPV1 receptors and demonstrates broad anti-inflammatory, sebostatic, and antimicrobial activity. Its widespread adoption has driven ingredient standardization, making it easier for formulators to source high-purity material at scale.

Research Supporting CBD and Its Skincare Benefits

A 2024 literature review in the American Journal of Clinical Dermatology examined pre-clinical and clinical studies on CBD for cosmetic dermatology, finding that CBD inhibits lipogenesis in sebocytes, reduces pro-inflammatory cytokine expression, and demonstrates wound-healing properties. 

The study highlighted CBD's ability to normalize "pro-acne agents"-induced excessive sebaceous lipid production, reduce keratinocyte proliferation, and alleviate inflammation in human sebocyte cultures. 

When tested in safety profiles, CBD at concentrations up to 10% (w/v) exhibited no cytotoxicity, mutagenicity, or skin sensitization, with absorbed doses reaching 242.41 μg/cm² over 24 hours. CBD also inhibited MMP-1 activity by over 60%, indicating potential to prevent collagen degradation in the extracellular matrix.

For formulators, this translates to a well-tolerated active with multi-pathway efficacy. CBD works by modulating inflammatory mediators (TNF-α, IL-1β, IL-6), reducing oxidative stress, and regulating sebum production, making it suitable for formulations targeting acne, rosacea, eczema, and aging skin. The compound's ability to reduce transepidermal water loss (TEWL) also supports its use in barrier-repair products.

Why Formulators Should Consider CBD

For teams evaluating which cannabinoids provide the widest formulation flexibility and market familiarity, CBD remains the most practical starting point.

• CBD offers a well-established safety profile and broad utility, making it suitable for both daily-use products and targeted treatment formats.

• Brands can work within a 0.1 percent to 3 percent concentration range, with higher levels typically reserved for more intensive, localized applications.

  
  

• Broad-spectrum CBD accounts for roughly 45% of the 2024 CBD skincare market, providing multi-cannabinoid benefits without THC and supporting stronger consumer acceptance of the entourage effect.

  
  

• CBD integrates effectively with anti-inflammatory co-actives such as niacinamide, azelaic acid, and centella asiatica, allowing for diversified product architectures across serums, creams, cleansers, and masks.

  
  

• Its lipophilic nature requires proper solubilization within oil phases or emulsions, but this characteristic also improves dermal penetration when systems are engineered correctly.

  
  

• For manufacturers entering cannabinoid skincare, CBD remains the lowest-risk option because supplier networks, testing infrastructure, and regulatory pathways are already well established.

Arvida Labs' CBD Isolate provides 99%+ purity CBD crystalline powder, ideal for precise dosing in skincare formulations. Sourced with full COA documentation and batch traceability, it offers formulators a clean, water-white isolate that dissolves readily in carrier oils and can be incorporated into both anhydrous and emulsion systems.

CBG (Cannabigerol)

CBG is emerging as a superior alternative to CBD in specific skincare applications, particularly for anti-inflammatory and barrier-strengthening formulations. Often called the "mother cannabinoid" because it serves as the precursor to THC, CBD, and CBC, CBG demonstrates unique receptor interactions that make it especially effective for combating environmental stressors and supporting skin regeneration.

Research Supporting CBG and Its Skincare Benefits

A clinical study published in Molecules (2022) evaluated biosynthetically produced CBG in human dermal fibroblasts and normal human epidermal keratinocytes, finding that CBG reduced reactive oxygen species levels better than vitamin C and inhibited pro-inflammatory cytokines (IL-1β, IL-6, IL-8, TNF-α) more effectively than CBD in several inflammatory scenarios.

Gene microarray analysis demonstrated that CBG regulates more genes than CBD, including key targets for collagen, elastin, and skin hydration. In the same study, a 20-subject vehicle-controlled clinical trial showed that 0.1% CBG serum produced statistically significant improvements over placebo for transepidermal water loss and reduction in redness appearance after sodium lauryl sulfate-induced irritation.

Why Formulators Should Consider CBG

Before selecting inputs for next-generation skincare systems, it helps to understand where CBG delivers meaningful technical advantages.

• CBG serves as a premium active for high-end skincare lines because its clinical data supports strong performance in environmental protection and barrier repair.

  
  

• Brands can position CBG strategically since it has been shown to outperform vitamin C in specific antioxidant assays, providing a credible claim for products targeting pollution-stressed skin.

  
  

• Research demonstrates that CBG and CBD both reduce pro-inflammatory cytokines triggered by urban particulate matter, strengthening their value in formulations designed to address environmental skin damage.

• CBG behaves similarly to CBD in terms of solubility and stability, yet it requires adjusted ratios when paired with other actives due to its distinct receptor activity.

• Formulations focused on inflammation, redness, and compromised barriers typically benefit from incorporating CBG at 0.1 percent to 1 percent based on clinical efficacy ranges.

  
  

• CBG performs particularly well in post-procedure recovery products, sensitive-skin lines, and anti-pollution formulations, making it a versatile and targeted option for advanced product development.

Arvida Labs' CBG Isolate delivers high-purity cannabigerol in crystalline form, suitable for incorporation into advanced anti-aging and barrier-repair formulations. Tested for purity and supplied with full documentation, this isolate allows formulators to create CBG-forward products backed by emerging clinical research showing superior anti-inflammatory activity compared to traditional botanical actives.

CBN (Cannabinol)

CBN occupies a unique position among cannabinoids due to its mild sedative properties and evidence for anti-inflammatory and antimicrobial activity. While primarily recognized for sleep-support applications in ingestible products, CBN's topical benefits are gaining attention for formulations targeting overnight skin repair and stress-related skin conditions.

Research Supporting CBN and Its Skincare Benefits

Preclinical studies suggest that CBN possesses mild sedative properties alongside anti-inflammatory activity at doses as low as 10 mg/kg, with demonstrated effects on reducing oxidative stress and supporting skin barrier function. 

CBN may help modulate inflammation, mechanisms relevant to conditions like acne, irritation, and premature aging, positioning it as a candidate for cannabinoid-based dermatological applications. While human clinical trials examining CBN for skincare remain limited, animal and in vitro studies demonstrate antibacterial properties and potential for reducing inflammatory markers.

The key differentiator for CBN is its formation pathway: it develops as THC degrades through oxidation, meaning it naturally occurs in aged hemp material. This gives CBN a distinct chemical profile compared to cannabinoids synthesized directly from CBGa. From the formulation side, this means CBN may work synergistically with other cannabinoids in full-spectrum or broad-spectrum blends, contributing to the entourage effect while providing unique calming benefits.

Why Formulators Should Consider CBN

For brands developing evening-focused or recovery-oriented skincare, CBN offers a distinct positioning opportunity that aligns naturally with PM routines.

• CBN provides a built-in marketing narrative as a nighttime cannabinoid, making it well-suited for PM skincare systems, overnight masks, and restorative formulations.

• Although its clinical data is less extensive than CBD or CBG, CBN’s anti-inflammatory activity and reported calming effects support its use in products designed for stress-reactive or evening-use applications.

• Early brand reports indicate that consumer associations with relaxation may translate into perceived skincare benefits, although these impressions must be managed carefully through compliant claims language.

• As far as regulations are concerned, CBN aligns closely with CBD due to its non-psychoactive or minimally psychoactive profile, making it suitable for cosmetic inclusion when sourced and documented properly.

• Most formulations incorporate CBN at 0.1 percent to 0.5 percent, commonly paired with CBD or CBG to strengthen anti-inflammatory performance and broaden functional claims.

• CBN’s lipophilic structure allows it to integrate seamlessly into oil-based serums, balms, and richer night-cream systems that benefit from its PM-aligned positioning.

Arvida Labs' CBN Isolate provides high-purity cannabinol for formulators developing nighttime skincare products or targeting stress-related skin concerns. Backed by complete COA documentation and batch consistency, this isolate allows brands to differentiate with emerging cannabinoid science while maintaining formulation reliability.

CBC (Cannabichromene)

CBC stands out among cannabinoids for its potent anti-acne and anti-inflammatory properties. Often overshadowed by CBD and CBG, CBC demonstrates unique sebostatic activity that makes it particularly valuable for formulations targeting oily, acne-prone skin and inflammatory dermatological conditions.

Research Supporting CBC and Its Skincare Benefits

A 2016 study published in Experimental Dermatology investigated the effects of CBC on human sebocyte functions, finding that CBC suppressed basal sebaceous lipid synthesis and significantly reduced arachidonic acid-induced "acne-like" lipogenesis. The same research demonstrated that CBC, along with CBDv and THCv, exhibited remarkable anti-inflammatory actions, leading researchers to conclude that these cannabinoids warrant consideration as efficient, safe tools in managing cutaneous inflammations. 

Research published in a 2023 synthetic review confirmed that CBC inhibits the proliferation of keratinocytes by targeting the Wnt/β-catenin signaling pathway, which controls skin cell proliferation: a mechanism relevant to psoriasis management.

What makes CBC particularly interesting for acne formulations is its dual-action approach: it reduces sebum production while simultaneously targeting inflammation. CBC exhibited powerful anti-inflammatory properties and suppressed excessive lipid production in sebaceous glands, while also reducing levels of arachidonic acid (AA), which is needed to create lipogenesis. This makes CBC more targeted than CBD for sebum-control applications, where reducing oil production is as important as managing inflammation.

Why Formulators Should Consider CBC

For developers focused on clearer-skin systems and non-irritating acne solutions, CBC offers a targeted mechanism that differs meaningfully from conventional actives.

• CBC demonstrates a strong anti-acne profile, making it highly suitable for blemish-control products, oil-regulating serums, and systems designed for acne-prone or seborrheic skin.

• Unlike common anti-acne actives that rely on exfoliation or desiccation, CBC modulates sebum production through endocannabinoid pathways, allowing effective oil management without compromising the skin barrier.

• Its non-irritating mechanism enables formulators to build acne treatments that reduce oil while avoiding the dryness associated with benzoyl peroxide or aggressive exfoliants.

• CBC performs especially well in lightweight gels, serums, and treatment lotions where its sebostatic properties can be focused on T-zone control or targeted spot applications.

• It pairs effectively with non-comedogenic co-actives such as niacinamide, zinc, and azelaic acid to improve overall efficacy and broaden treatment coverage.

• Typical usage levels range from 0.5 percent to 2 percent, depending on severity, frequency of application, and whether the formula is intended for all-over or localized use.

• Formulators sourcing CBC should prioritize suppliers that have products with validated purity and third-party screening for psychoactive cannabinoids, as CBC is sometimes present in full-spectrum extracts alongside trace amounts of THC.

CBDv (Cannabidivarin)

CBDv is a homolog of CBD with two fewer carbon atoms in its side chain, giving it distinct pharmacological properties despite structural similarity. While research on CBDv for skincare is still ongoing, early studies suggest it may be particularly effective for acne, sensitive skin, and inflammatory conditions like atopic dermatitis.

Research Supporting CBDv and Its Skincare Benefits

The same 2016 Experimental Dermatology study that evaluated CBC also examined CBDv, finding that CBDv significantly reduced arachidonic acid-induced acne-like lipogenesis, though it had only minor effects on basal sebaceous lipid synthesis. This suggests CBDv's primary mechanism is moderating inflammation-triggered sebum production rather than baseline oil levels, making it potentially useful for reactive or hormonally influenced acne. 

Why Formulators Should Consider CBDv

For brands looking for a cannabinoid that offers differentiation without disrupting existing formulation systems, CBDv provides a compelling emerging option.

• CBDv positions itself as a complementary or alternative active to CBD, giving brands a credible way to introduce next-generation cannabinoid formulations in acne-focused and sensitive-skin portfolios.

• Its early research profile enables marketers to frame CBDv products for innovation-driven consumers, especially in categories where brands want to lead with novelty and scientific storytelling.

• CBDv is somewhat similar to CBD in terms of solubility and incorporation, allowing formulators to substitute or combine the two with minimal adjustment to existing systems.

• Limited commercial availability means formulators should anticipate higher input costs and longer sourcing timelines, particularly compared to more established cannabinoids such as CBD, CBG, or CBN.

• Typical usage levels would mirror CBD at approximately 0.1 percent to 3 percent, with adjustments made after stability assessments and functional testing.

• CBDv offers strategic value for brands focused on niche applications such as hormonal acne or atopic dermatitis, where differentiation and early-stage research can support premium positioning.

• Brands pursuing CBDv should work closely with suppliers who provide thorough analytical profiles and are able to discuss realistic applications grounded in the currently limited but expanding research base.

Formulation Considerations for Cannabinoid Skincare Products

Formulators working with cannabinoids must account for the unique chemical behavior of these compounds to guarantee stability, bioavailability, and long-term product consistency. The following considerations outline the core technical factors that determine whether a cannabinoid topical will perform as intended.

Solubility and Base System Selection

Incorporating cannabinoids into skincare requires careful attention to solubility, dispersion, and delivery. Cannabinoids are lipophilic molecules that must be properly incorporated to maintain bioavailability. Effective systems include oil-in-water emulsions, anhydrous serums, and carrier-oil formulations designed to support dermal penetration.

Stability Requirements and Packaging Controls

Stability is a primary concern when formulating with cannabinoids. These compounds oxidize in the presence of light, heat, and oxygen, so formulas should include antioxidants such as vitamin E, rosemary extract, or astaxanthin. Packaging choices like airless pumps and opaque containers help protect actives, and accelerated stability testing should track cannabinoid degradation over time.

Dosing Guidelines for Topical Efficacy

Topical dosing differs significantly from ingestible formats. While oral CBD may require 10–50 mg per dose, topical efficacy is achieved at lower concentrations due to localized delivery. Clinical studies for CBD, CBG, and CBN normally support use levels between 0.1 percent and 3 percent, with higher percentages reserved for targeted treatment products.

Manufacturing Partnerships and Supply Chain Considerations

Brands scaling cannabinoid skincare should prioritize manufacturing partners with proven cannabinoid-handling experience to create consistent quality and adhere to regulatory compliance. Formulators developing proprietary systems benefit from using pre-tested cannabinoid isolates from reputable suppliers, which reduces formulation risk and supports faster progression from R&D to market-ready production.

Closing Thoughts — How Arvida Labs Supports Manufacturers Who Formulate Skin Products

The cannabinoid skincare category is moving from trend to science-backed formulation standard. Brands that succeed in this space will be those that prioritize ingredient quality, formulation expertise, and transparent claims substantiation. 

Arvida Labs supplies high-purity CBD, CBG, and CBN isolates with full COA documentation, batch traceability, and formulation support for brands developing targeted skincare products.

Whether you're launching a new line or reformulating existing products with cannabinoid actives, partnering with a manufacturer that understands both the chemistry and the compliance aspect is non-negotiable. 

Arvida Labs works with wellness brands, private-label manufacturers, and contract formulators to deliver consistent, compliant cannabinoid ingredients backed by third-party testing. 

If you’re looking to scale cannabinoid skincare products with confidence, partner with Arvida Labs to source high-quality CBD, CBG, and CBN today.

Frequently Asked Questions About Cannabinoids in Skincare

Which Cannabinoid Is Most Effective for Treating Acne-Prone Skin?

CBC and CBDv demonstrate the strongest anti-acne activity based on current research. CBC suppresses sebaceous lipid synthesis and reduces arachidonic acid-induced lipogenesis, while CBDv moderates inflammation-triggered sebum production. CBD remains effective through anti-inflammatory and antimicrobial pathways. For oily, acne-prone skin formulations, CBC at 0.5-2% concentrations combined with niacinamide or zinc delivers optimal results.

Can Cannabinoids Be Combined With Retinoids or AHAs in Skincare Formulations?

Yes, cannabinoids can be combined with retinoids and alpha-hydroxy acids with careful pH and stability management. Retinoids and AHAs function optimally at lower pH ranges while cannabinoids remain stable across broader ranges. CBD and CBG's anti-inflammatory properties may mitigate retinoid irritation. Formulators should conduct stability testing and consider phased-release systems or separate AM/PM products for maximum efficacy.

What Concentration of Cannabinoids Should Be Used for Anti-Inflammatory Effects?

Clinical studies demonstrate anti-inflammatory efficacy at 0.1% to 3%, depending on cannabinoid and application. CBG showed significant benefits at 0.1% in clinical trials, while CBD requires 1-3%. Daily-use products benefit from 0.5-1.5% concentrations, while targeted treatments can use 2-3%. Brands should conduct consumer testing to determine optimal concentrations for their specific formulations and positioning.

How Do Cannabinoids Compare to Traditional Anti-Aging Ingredients Like Vitamin C or Peptides?

Cannabinoids work through different mechanisms than traditional anti-aging actives, making them complementary. While vitamin C stimulates collagen synthesis, cannabinoids reduce inflammaging by modulating cytokine expression. CBG outperforms vitamin C in certain antioxidant assays, while CBD inhibits MMP-1 activity, preventing collagen degradation. Optimal anti-aging formulations combine cannabinoids with peptides, antioxidants, and retinoids for multi-pathway efficacy.

Are Cannabinoid Skincare Products Safe for Sensitive or Eczema-Prone Skin?

Safety studies confirm CBD and CBG exhibit no cytotoxicity, mutagenicity, or skin sensitization at concentrations up to 10μM. Their anti-inflammatory properties make them suitable for sensitive or eczema-prone skin. Full product safety depends on complete formulation. Brands should conduct patch testing and HRIPT studies on finished formulations. Cannabinoids with proper COAs free from contaminants are well-tolerated across skin types.

What Is the Difference Between Full-Spectrum, Broad-Spectrum, and Isolate Cannabinoids for Skincare?

Full-spectrum extracts contain all cannabinoids, including trace THC, terpenes, and flavonoids. Broad-spectrum contains multiple cannabinoids with THC removed. Isolates are 99%+ pure single cannabinoids. For skincare, broad-spectrum and isolate forms are most common due to regulatory clarity and precise dosing. The choice depends on the target market, regulatory requirements, and formulation goals, including desired entourage effects.

How Should Brands Substantiate Anti-Inflammatory or Anti-Acne Claims for Cannabinoid Products?

Claims substantiation requires ingredient-level research, formulation testing, and consumer studies. Brands can reference peer-reviewed research but should conduct in vitro testing on final formulations. Anti-acne claims need clinical trials measuring sebum production and lesion counts. Anti-inflammatory claims require cytokine expression studies or clinical trials measuring erythema and TEWL. Working with dermatologist-reviewed protocols ensures FTC substantiation standards.

Sources for This Article

• PubMed: "Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin" - pubmed.ncbi.nlm.nih.gov/15927811/

• PMC: "The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities" - pmc.ncbi.nlm.nih.gov/articles/PMC2757311/

• PMC: "Cannabinoid Signaling in the Skin: Therapeutic Potential of the "C(ut)annabinoid" System" - pmc.ncbi.nlm.nih.gov/articles/PMC6429381/

• MDPI: “Exploring Cannabidiol (CBD) and Cannabigerol (CBG) Safety Profile and Skincare Potential” - mdpi.com/1422-0067/25/22/12224

• Springer: “Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases—A Synthetic Review” - link.springer.com/article/10.1007/s40257-024-00891-y

• Deep Market Insights: "CBD Skincare Market Size, Trends & Growth Analysis By 2030" - deepmarketinsights.com/report/cbd-skincare-market-research-report

• PMC: "Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder ('CUPID' study): protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial" - pmc.ncbi.nlm.nih.gov/articles/PMC10450062/

• ScienceDirect: “Health benefits, pharmacological properties, and metabolism of cannabinol: A comprehensive review” - sciencedirect.com/science/article/pii/S0926669024003364

• PMC: "The Antimicrobial Activity of Cannabinoids" - pmc.ncbi.nlm.nih.gov/articles/PMC7400265/

• PMC: "Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases—A Synthetic Review" - pmc.ncbi.nlm.nih.gov/articles/PMC10459035/